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CDC DENV-1-4 Real-Time RT-PCR Assay 

for Detection and Serotype Identification of 
Dengue Virus 
1. INTENDED USE 
The CDC DENV‐1‐4 Real‐Time RT‐PCR Assay is intended for use on an Applied Biosystems (ABI) 7500 Fast Dx 
Real‐Time PCR Instrument: 
 For the diagnosis of dengue in serum or plasma collected from patients with signs and symptoms 
consistent with dengue (mild or severe) during the acute phase; 
 For the identification of dengue virus serotypes 1, 2, 3 or 4 from viral RNA in serum or plasma 
(sodium citrate) collected from human patients with dengue during the acute phase; 
 To provide epidemiologic information for surveillance of circulating dengue viruses. 
Testing of clinical blood specimens (serum or plasma) with the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay 
should not be performed unless the patient meets clinical and/or epidemiologic criteria for testing suspect 
dengue cases. 
The CDC DENV‐1‐4 Real‐Time RT‐PCR Assay is not FDA cleared or approved for the screening of blood or 
plasma donors. 
Negative results obtained with this test do not preclude the diagnosis of dengue and should not be used as 
the sole basis for treatment or other patient management decisions. 
This device is for distribution to laboratories with personnel who have training and experience in 
standardized molecular diagnostic testing procedures and viral diagnosis, and appropriate biosafety 





                                 
                                 
                             
                                   
                                     
                               
                               
                               
                                   
                                      
 
                         
                                 
                                   
                               
                                 
                                   
                         
                                 
                         
                               
                       
                             
           
 
                                   
                                     
                                   
                                       
                                   
                               
                                 
            
 
                               
                                     
        
 
2. SUMMARY AND EXPLANATION 
Dengue is an illness caused by infection with any one of four related dengue virus (DENV) serotypes (DENV‐
1, ‐2, ‐3 and ‐ 4) which are transmitted by Aedes sp mosquitoes, and affects an estimated 50 million people 
in approximately 100 countries annually (1). Infection by one DENV serotype confers long‐term immunity to 
that serotype but not to the other three. Therefore, in dengue endemic countries, people are likely to be 
infected more than once over their lifetime. In the United States, dengue is endemic in Puerto Rico (2‐4) the 
Virgin Islands (5, 6), and American Samoa and other U.S.‐affiliated Pacific Islands. In non‐endemic areas of 
the United States, dengue is the most frequent cause of febrile illness among travelers returning from 
tropical or subtropical areas of the Caribbean, Latin America and Asia (7). In addition, occasional outbreaks 
occur in areas of the United States where the vector mosquito is present, such as along the U.S.‐Mexico 
border (8, 9), Florida (10, 11), and Hawaii (12). In the United States dengue is a nationally notifiable disease. 
The majority (~75%) of DENV infections are asymptomatic. Among persons with symptomatic DENV 
infection (dengue), the illness occurs in three phases (1). During the acute phase, the principal symptom is 
2–7 days of fever, which is often accompanied by one or more of the following: headache, retro‐orbital eye 
pain, joint pain, muscle and/or bone pain, rash, mild bleeding manifestations (e.g., nose or gum bleed, 
petechiae, or easy bruising) and low white cell count. The critical phase of dengue begins at defervescence 
which marks a 24 to 48 hour period in which compensated or decompensated shock may occur due to 
increased capillary permeability with plasma leakage that produces ascites, pleural effusions and “third 
spacing” of fluids. The presence of these signs and/or symptoms is now called severe dengue rather than 
dengue hemorrhagic fever or dengue shock syndrome. Without appropriate treatment, patients with severe 
dengue are at risk of death. Other warning signs of severe dengue include abdominal pain, vomiting, 
thrombocytopenia and mild to severe hemorrhagic manifestations, including tendency to bruise easily, 
petechiae, menorrhagia and mucous membrane bleeding of the nose or gums. The convalescent phase of 
dengue lasts for 4‐7 days (1). 
Laboratory diagnosis of dengue is best made during the acute phase of the illness when DENV circulates in 
the blood and can be detected by assays to detect the viral RNA genome (13‐15) or soluble antigens (i.e., 
NS1 antigen) (16). Anti‐DENV IgM antibody to DENV is also produced during the acute phase of the illness 
and becomes detectable by ELISA at days 3‐5 after onset of fever (17, 18). At this point the optimum testing 
algorithm for dengue has not yet been determined. If results of the DENV detection test (e.g., RT‐PCR) are 
negative (days 1‐5 after fever onset), anti‐DENV IgM testing should be considered. If the patient first 
presents during the critical or convalescent phases of the illness, laboratory diagnosis is best made using a 
test for IgM antibody to DENV. 
The CDC DENV‐1‐4 Real‐Time RT‐PCR Assay is a nucleic acid amplification assay that detects DENV serotypes 
1, 2, 3 or 4 RNA from human serum or plasma collected from human patients with signs and symptoms 




                                   
                           
                                   
                               
                               
                           
                                 
                               
 
                               
                               
                                   
                                     
                                 
                               













2.1 Principles of the Procedure 
The CDC DENV‐1‐4 Real‐Time RT‐PCR Assay is used in rRT‐PCR on an ABI 7500 Fast Dx Real‐Time PCR 
Instrument. The CDC DENV‐1‐4 Real‐Time RT‐PCR Assay includes a set of oligonucleotide primers and dual‐
labeled hydrolysis (Taqman®) probes for in vitro qualitative detection of DENV serotypes 1, 2, 3 or 4 from 
serum or plasma collected from human patients with signs and symptoms consistent with dengue (mild or 
severe). The targeted regions of viral RNA are transcribed into complementary (cDNA) and amplified by the 
polymerase chain reaction (PCR). The fluorescently labeled probes anneal to amplified DNA fragments and 
the fluorescent signal intensity is monitored by the ABI 7500 Fast Dx instrument during each PCR cycle. 
Amplification of target is recorded as increase of fluorescence over time in comparison to background signal. 
A positive control virus mix is also included, which consists of heat‐inactivated DENV‐1 Haw, DENV‐2 NGC, 
DENV‐3 H87, and DENV‐4 H241. A Human Specimen Control (HSC) is a noninfectious cultured human cell 
material that provides a positive signal in the assay and demonstrates successful recovery of RNA as well as 
the integrity of the RNA extraction reagent. The human RNase P RNA (RP) is present in cultured cell material 
and in most clinical samples and detectable by RT‐PCR using the primers and probes provided. The CDC 
DENV‐1‐4 Real‐Time RT‐PCR Assay can be run in singleplex (each DENV serotype detected in a separate 
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and Probes, aliquot 
and store 
Dilute DENV‐1‐4 RNA 
1:10 
Extract DENV‐1‐4 RNA 
Extract Samples RNA and HSC RNA 
Prepare Master Mix (20 μL) 
Prepare RT‐PCR Plate (5 μL RNA) 
Run CDC RT‐PCR Assay on 









         
              
                
                          
              
 
               
                 
     
   
           
           
           
           
           
           
           
             
             
             
         
         
         
         
           
 
  
4. MATERIALS PROVIDED 
CDC DENV‐1‐4 Real‐Time RT‐PCR Assay: 
1‐ Package Insert/ Instructions for Use (this brochure) 
2‐ Box 1: Detection Kit (Primer and Probe Sets) 
3‐ Box 2: Positive Control Kit (a mix of heat inactivated DENV‐1, ‐2, ‐3 and ‐4 standards) 
4‐ Box 3: Human Specimen Extraction Control (HSC) 
Box 1: Detection Kit (Primer and Probe Sets) 
(Store at 2‐8 oC in PCR Reagent Preparation Area) 




D1‐F SO3504 DENV‐1 Forward Primer 5 nmol 200 
D1‐R SO3505 DENV‐1 Reverse Primer 5 nmol 200 
D2‐F SO3507 DENV‐2 Forward Primer 5 nmol 200 
D2‐R SO3508 DENV‐2 Reverse Primer 5 nmol 200 
D3‐F SO3510 DENV‐3 Forward Primer 5 nmol 200 
D3‐R SO3511 DENV‐3 Reverse Primer 5 nmol 200 
D4‐F SO3513 DENV‐4 Forward Primer 5 nmol 200 
D4 R SO3514 DENV‐4 Reverse Primer 5 nmol 200 
RP‐F SO2669 RNase P Forward Primer 5 nmol 200 
RP‐R SO2670 RNase P Reverse Primer 5 nmol 200 
D1‐Probe SO3506 DENV‐1 Probe 1 nmol 200 
D2‐Probe SO3509 DENV‐2 Probe 1 nmol 200 
D3‐Probe SO3512 DENV‐3 Probe 1 nmol 200 
D4‐Probe SO3515 DENV‐4 Probe 1 nmol 200 




                   
     











         
             
         
       
       
       
         
     
       






            








             
         
         
         
           
           
       
             
             
           
         
     
         












(Store at ‐20 oC in RNA Handling Area) 
Reagent 
Label 






SO3517 Dengue virus serotypes 1‐4 
mix for use as a positive control 
in the CDC DENV‐1‐4 Real‐Time 
RT‐PCR Assay procedure to 
ensure the detection of DENV‐
1, DENV‐2, DENV‐3 and DENV‐
4. Dengue virus serotypes 1‐4 
mix contains heat‐inactivated 
DENV‐1 Haw, DENV‐2 NGC, 
DENV‐3 H87 and DENV‐4 H241. 
1 mL 4 
Box 3: Human Specimen Extraction Control 
(Store at ‐20 oC in Nucleic Acid Extraction Room) 
Reagent 
Label 




HSC HS0096 Human Specimen Control: For use as 
an RNA extraction procedural control 
with the CDC DENV‐1‐4 Real‐Time RT‐
PCR Assay to demonstrate successful 
recovery of RNA from human serum 
or plasma samples. Purified RNA from 
Human Specimen Control material 
should yield a positive result with the 
RP primer and probe set and negative 
result with all DENV specific markers. 
The HSC consists of non‐infectious 
(beta propiolactone inactivated) 
cultured human cell material supplied 
as a liquid suspended in 0.01 M PBS at 
pH 7.2–7.4. 






                                   
                         
 

















             
         
 
 
    
 
           
         
        
                                     
                                       
                       
                                       
                               
 
  
            
          
          
            
      
    
        
          
      
      





                                
           
          
                      
   
        
 
5. MATERIALS REQUIRED (BUT NOT PROVIDED)
5.1 Reagents 
The following is a list of ancillary reagents that are not supplied with the CDC DENV‐1‐4 Real‐Time RT‐PCR 
Assay. The Invitrogen and Roche products are included in CDC’s reagent qualification program. 
Reagents Quantity Catalog # 
rRT‐PCR 
Enzyme 
Invitrogen SuperScript™ III Platinum® 











Qiagen QIAamp® DSP Viral RNA Mini Kit 





Kit Options Roche MagNA Pure LC total Nucleic 
Acid Isolation Kit * 
192 
Extractions 
03 038 505 001 
*The CDC DENV‐1‐4 Real‐Time RT‐PCR Assay test performance requires that only qualified ancillary reagent lots be used with the 
device. Any lots not specifically qualified by the CDC‐Dengue Branch for use with the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay are 
not valid for use with this device, and may affect device performance. 
** Qiagen QIAamp® DSP Viral RNA Mini Kit (Cat # 61904) is produced under Good Manufacturing Practices (GMP). These RNA 
extraction kits can be used manually or in combination with the QIAcube Instrument (Cat # 9001292). 
5.2 Equipment and Consumables Required (But Not Provided)
 RNAse/DNase‐free 1.5 ml polypropylene microcentrifuge tubes 
 Molecular grade water (RNase/DNase Free) 
 Sterile nuclease‐free filtered pipette tips 
 Micropipettors (1, 1‐10, 10‐200 and 100‐1000 μL) 
 96‐well cold block 
 Benchtop Microcentrifuge 
 Personnel Protective Equipment (PPE) 
 ‐70o C and ‐20 oC Freezer(s) 
 +4o C Refrigerator 
 Plasticware and consumables 
 100% Ethanol (EtOH) 
 10% bleach 
 Disposable gloves 
 DNAzap™ 
 RNase AWAY® 
 MagNA Pure LC 2.0 instrument (05 197 686 001) for automated RNA extractions using MagNA Pure 
LC total Nucleic Acid Isolation Kit 
 MagNAPure LC 2.0 system consumables 
 QIAcube Purification instrument (9001292), optional for RNA extractions using Qiagen RNA 
extraction kits 





                        
                
                         
                            
      
                              




                               
                                 
                             
                  
                              
                                 
          
                              
                    
                              
                           
             
 
                         
             
 







                                    
                          
          
                                  
               
                              
 Applied Biosystems 7500 Fast Dx Real‐time PCR instrument (4406984) with System Sequence 
Detection 1.4 Software (Applied Biosystems, Foster City, CA) 
 Applied Biosystems 7500 Fast Sequence Detection Consumables (Applied Biosystems, Foster City, CA) 
 ABI MicroAmp™ Fast 8‐tube strip 0.1 mL, cat#4358293 (required), or ABI MicroAmp™ Optical 8‐cap 
strip, cat#4323032 (required) 
 ABI MicroAmp™ Fast Optical 96‐Well Reaction Plate with (0.1 mL), part #4346906 (with barcode) or 
#4346907 (without barcode), or part 4366932 (alternate to 8‐strip tubes) 
6. IMPORTANT PUBLIC HEALTH SURVEILLANCE INFORMATION
Dengue is a nationally notifiable disease in the United States and patients testing positive with CDC DENV‐1‐
4 Real‐Time RT‐PCR Assay or for IgM anti‐DENV should be reported to state, local or territorial health 
departments. Clinicians should have a high level of suspicion and consider dengue diagnostic testing among 
patients with acute febrile illness in the following settings: 
1. In dengue endemic areas of the United States (e.g., Puerto Rico, Virgin Islands, U.S.‐affiliated Pacific 
Islands) in patients with acute febrile illness of 1‐8 days duration with or without signs and symptoms 
of mild or severe dengue; 
2. Among recently returning travelers from tropical areas with an acute febrile illness of 1‐8 days 
duration with or without symptoms of mild or severe dengue; 
3. Patients in areas of the United States that have previously experienced dengue outbreaks or have 
DENV competent vectors (e.g., U.S.‐Mexico border, Florida) with an acute febrile illness with or 
without symptoms of mild or severe dengue. 
CDC offers reference diagnostic testing and consultation for suspect dengue cases. Please visit 
http://www.cdc.gov/dengue for clinical and laboratory guidelines. 







7. REAGENT STORAGE, HANDLING, AND STABILITY 
 Store all primers and probes at 2–8o C until re‐hydrated for use; store all control materials at ‐20o C.
 
 Always check the expiration date prior to use. Do not use expired reagents.
 
 Protect fluorogenic probes from light.
 
 Primers, probes (including aliquots), and enzyme master mix must be thawed and kept on ice or cold
 
block at all times during preparation and use. 







                           
                             
 
 
                                 
                                             
                          
 
                              
                        
                         
                                         
                                 
                       
                                
                             
               
 
                          
                 
                  
 
 
                              
                 
   
8. SPECIMEN COLLECTION, HANDLING AND STORAGE 
Inadequate or inappropriate specimen collection, storage, and transport are likely to yield false negative 
test results. Training in specimen collection is highly recommended due to the importance of specimen 
quality. 
To diagnose dengue, the laboratory requires a blood sample taken during the acute period of the disease 
(first 7 days of symptoms). If the patient makes the first visit to the physician on or after day 7 of onset of 
the symptoms, that sample is likely to not render a positive RT‐PCR result. 
8.1 Collecting the Specimen 
	 Once there is a clinical diagnosis of suspected dengue, take a venous, whole blood sample. 
	 Follow serum or plasma specimen collection devices manufacturer instructions for proper collection, 
separation and storage methods. We recommend that separated serum or plasma samples are 
frozen at ‐20 oC and sent or shipped in dry ice to the testing laboratories. If dry ice is not available, we 
recommend that separated serum or plasma is maintained on ice or in a refrigerator for no longer 
than 2 hours before it is either frozen at ‐20 oC or tested. 
	 All serum samples used for the validation of the CDC DENV‐1‐4 RT‐PCR assay were derived from 
blood samples collected in red‐top or in serum separator tubes (red marble or tiger‐top). Sodium 
Citrate plasma was used for analytical sensitivity studies. 
8.2 Transporting the Specimen 
 Ensure that when transporting human blood, plasma or serum specimens, all applicable regulations 
for transport of potentially infectious biological specimens are met. 
 Transport/ship human serum or plasma samples in dry ice. 
8.3 Storing Specimens
	 Store specimens at  ‐20 oC upon receipt. Thaw sample and keep on ice during sample processing. 






                        
                                  
 
                            
             
                        
           
 
           
       
   
           
         
     
       
 




                    
  
              
                                      
   
                          
                            
  
                            
 
        






                              
9. SPECIMEN REFERRAL TO CDC 
	 Ship all specimens and related RNA overnight to the CDC Dengue Branch. 
	 Ship frozen specimens on dry ice and non‐frozen specimens on cold packs. Ship extracted RNA on dry 
ice. 
	 Refer to the International Air Transport Association (IATA – www.iata.org) for requirements for shipment 
of human or potentially infectious biological specimens). 
	 For more information about specimen referral, please contact ckq2@cdc.gov. Sample management and 
shipping can be found at http://www.cdc.gov/dengue. 
Send samples to the following recipient: 
Chief of Molecular Diagnostics 
Dengue Branch 
Centers for Disease Control and Prevention 
Att. Dr. Jorge L. Munoz‐Jordan 
1324 Cañada Street 
San Juan, PR 00920 
The emergency contact number for CDC Emerging Operation Center (EOC) is 770‐488‐7100. 
10. REAGENTS AND CONTROLS PREPARATION
10.1 Primer and Probe Preparation 
1. Upon receipt, store lyophilized primers and probes at 2‐8 °C. 
2. Rehydration 
a. Remove primers and probes from 2‐8 °C. 
b. Pipette 0.1 ml (100 μL) of 10 mM Tris, pH 7.4 ‐ 8.2 or PCR‐grade water into each dried PCR primer 
or probe. 
c. Allow primers and probes to fully rehydrate for 1 hour at room temperature. 
d. After primers and probes are fully rehydrated, pulse vortex to ensure a homogeneous solution. 
3. Aliquot 
a. Label one (1) nuclease‐free, sterile, tube for each primer and probe with the following 
information: 
i. Primer or Probe name 
ii. Kit Lot # 
iii. Expiration date 
4. Storage 
a. After rehydration 
i. Primers 





                              
  
                              
       






                            
          
  





                                 
          
                      
      




                           
                                
             
 
     
                                    
     
                
                    
                                
       
 
2.	 Thawed aliquots of primers may be stored at 2‐8 °C for up to 3 months. 
ii. Probes 
1.	 Aliquots of probes are stored at ‐20°C or below until expiration date as long as QC 
requirements are met. 
2.	 Thawed aliquots of probes may be stored at 2‐8 °C in the dark for up to 3 months.
10.2 Human Specimen Control (HSC) Preparation 
1. Reagent 
a. Noninfectious cultured human cell material supplied as a liquid suspended in 0.01 M PBS. 
b. Volume: 1 mL per vial. 
2. Storage 
a. Store at ‐20 °C or below upon receipt. DO NOT DILUTE. 
10.3. DENV-1-4 Positive Control Mix Preparation 
1. Reagent 
a. Inactivated, noninfectious DENV‐1‐4 Mix is supplied as a liquid suspended in normal human 
serum in four separate tubes. 
b. Each tube contains enough DENV‐1‐4 Mix for approximately 7 extractions. 
2. Storage 
a. Store at ‐20 oC or below upon receipt. Do not dilute. 
10.4 General Preparation 
Equipment Preparation 
Clean and decontaminate all work surfaces, pipettes, centrifuges, and other equipment prior to use. 
Decontamination agents should be used such as 5% bleach, 70% ethanol, DNAzap™ or RNase AWAY® to 
minimize the risk of nucleic acid contamination. 
Real‐time RT‐PCR Reagents 
 Place Invitrogen 2X PCR Master Mix and Superscript III RT / Platinum Taq enzyme mix in a cold 
rack at 4‐8°C. 
	 Completely thaw the 2X PCR Master Mix vial. 
	 Mix the 2X PCR Master Mix by inversion 10 times. 
	 Briefly centrifuge 2X PCR Master Mix and Superscript III RT / Platinum Taq enzyme mix, then 





          
                        
         
                                  
     
                            
                 
               
                        
                                  
                         
       
                                
               
                      
                    
                         
                              
 
                  
                        
                        
                             
                 
                                
   
                          
          
                              
               








11. WARNINGS AND PRECAUTIONS 

	 For in‐vitro diagnostic use (IVD). 
	 Follow standard precautions. All patient specimens and positive controls should be considered 
potentially infectious and handled accordingly. 
	 Do not eat, drink, smoke, apply cosmetics, or handle contact lenses in areas where reagents and human 
specimens are handled. 
	 Handle all specimens as if infectious using safe laboratory procedures. Refer to Biosafety in 
Microbiological and Biomedical Laboratories (BMBL) 5th Edition BMBL. (http://www.cdc.gov/biosafety/) 
for standard biological safety guidelines for all procedures. 
	 Specimen processing should be performed in accordance with national biological safety regulations. 
	 Use personal protective equipment such as (but not limited to) gloves and lab coats when handling kit 
reagents while performing this assay and handling materials including samples, reagents, pipettes, and 
other equipment and reagents. 
	 Due to the sensitivity of Real‐time RT‐PCR assays, special precautions must be followed to avoid false 
positive amplifications. The following precautionary steps are recommended. 
o	 Maintain separate areas for assay setup and handling of nucleic acids. 
o	 Maintain separate, dedicated equipment (e.g., pipettes, microcentrifuges) and supplies (e.g., 
microcentrifuge tubes, pipette tips) for assay setup and handling of extracted nucleic acids. 
o	 Wear a clean lab coat and powder‐free disposable gloves (not previously worn) when setting up 
assays. 
o	 Change gloves between samples and whenever contamination is suspected. 
o	 Keep reagent and reaction tubes capped or covered as much as possible. 
o	 Work surfaces, pipettes, and centrifuges should be cleaned and decontaminated with cleaning 
products such as 5% bleach, DNAzap™ or RNase AWAY to minimize risk of nucleic acid 
contamination. Residual bleach should be removed using 70% ethanol. 
	 Reagents, master mix, and RNA should be maintained on cold block during preparation and/or use to 
ensure stability. 
	 Always check the expiration date prior to use. Do not use expired reagents. 
	 Protect fluorogenic probes from light. 
	 Primers, probes (including aliquots), and enzyme master mix must be thawed and maintained on cold 
block at all times during preparation and use. 






                            
                         
                                 
       
                                
                             
             
                                  
                                     
       
                                      
   
 
                               
                           






               
 
                             
 
                           
                            
   
12. NUCLEIC ACID (RNA) EXTRACTION 
Performance of the CDC DENV‐1‐4 Real‐Time RT‐PCR Detection Assay is dependent on the amount and 
quality of template RNA purified from human specimens. The following commercially available RNA 
extraction kits and procedures have been qualified and validated for recovery and purity of DENV RNA for 
use with the Assay: 
1. QIAamp® DSP Viral RNA Mini Kit (Qiagen, CAT# 61904). This kit is produced under GMP; therefore, 
CDC does not monitor stability of this kit. These RNA extraction procedures can be performed 
manually or in the QIAcube Instrument (9001292). 
2. Roche MagNA Pure LC total Nucleic Acid Isolation Kit (03‐038 505 001) for viral RNA extraction on 
The Roche MagNA Pure LC 2.0 (05 197 686 001). This procedure is to be run using Roche MagNA 
Pure system products only. 
3. Store extracted RNA at ‐20 oC if PCR is to be done within 24 hours; otherwise, keep remaining RNA at 
‐80 oC. 
Disclaimer: Manufacturer’s recommended procedures are to be used for sample extraction with any of the 2 
above mentioned RNA extraction procedures. Names of vendors or manufacturers are provided as examples 
of suitable product sources. Inclusion does not imply endorsement by the Centers for Disease Control and 
Prevention.
13. ASSAY SETUP
13.1 Master Mix Preparation/Plate Setup 
Prepare Master Mix according to the following tables.
 
Note: It is necessary to make excess reaction master mix to allow for pipetting error.
 
Example: if number of samples (n) including controls = 1‐14, the N = n+1 




           
                                
                          
                            
                         
                         
                         
   
   
                    
         
                                   
   
 
         
                                
                              
                        
                                
                             
                           
                          
                           
                           
                           
                           
                       
   
   
                      
           
 
   
Example of Singleplex Reaction (any serotype)* 
Reagent Volume Volume/rx Total Number Reactions (N=10+1) Total Volume 
Nuclease‐free Water 5.55 μL N x 5.55 μL N = 10 + 1 = 11 61.05μL 
2X PCR Master Mix 12.5 μL N x 12.5 μL N = 10 + 1 = 11 137.5 μL 
Forward Primer 0.5 μL N x 0.5 μL N = 10 + 1 = 11 5.5 μL 
Reverse Primer 0.5 μL N x 0.5 μL N = 10 + 1 = 11 5.5 μL 
DENV Probe 0.45 μL N x 0.45 μL N = 10 + 1 = 11 4.95 μL 
SuperScriptTM III 
RT/Platinum®Taq Mix 
0.5 μL N x 0.5 μL N = 10 + 1 = 11 5.5 μL 
Total Volume 20 μL N x 20 μL 220 μL 
*To complete the CDC DENV‐1‐4 RT‐PCR Assay in singleplex mode, four separate reactions, one for each serotype, must 
be performed. 
Example of Multiplex DENV‐1, ‐2, ‐3,‐4 Reactions 
Reagent Volume Volume/rx Total Number Reactions (N) Total Volume 
Nuclease‐free Water 2.2 μL N x 2.2 μL N = 10 + 1 = 11 24.2 μL 
2X premix 12.5 μL N x 12.5 μL N = 10 + 1 = 11 137.50 μL 
Primer D1‐F 0.5  μL N x 0.5 μL N = 10 + 1 = 11 5.5 μL 
Primer D1‐R 0.5  μL N x 0.5 μL N = 10 + 1 = 11 5.5 μL 
Primer D2‐F 0.25 μL N x 0.25 μL N = 10 + 1 = 11 2.75 μL 
Primer D2‐R 0.25 μL N x 0.25 μL N = 10 + 1 = 11 2.75 μL 
Primer D3‐F 0.5  μL N x 0.5 μL N = 10 + 1 = 11 5.5 μL 
Primer D3‐R 0.5  μL N x 0.5 μL N = 10 + 1 = 11 5.5 μL 
Primer D4‐F 0.25 μL N x 0.25 μL N = 10 + 1 = 11 2.75 μL 
Primer D4‐R 0.25 μL N x 0.25 μL N = 10 + 1 = 11 2.75 μL 
Probes (DENV‐1‐4) 0.45 μL N x 0.45 μL N = 10 + 1 = 11 4.95 μL 
SuperScriptTM III 
RT/Platinum®Taq Mix 
0.5 μL N x 0.5 μL N = 10 + 1 = 11 5.5 μL 





       
                     
                                
                       
                         
                      
                      
                     
   
   
                 
         
 
              
          
                
                
                                
 
 
          
 
                               
         
                                
                       
 
                        
 
           
Example of HSC Reaction
 
(This reaction is run separate from either singleplex or multiplex reactions)
 
Reagent Volume Volume/rx Total Number Reactions (N=10+1) Total Volume 
Nuclease‐free Water 5.5 μL N x 5.5 μL N = 10 + 1 = 11 60.5 μL 
2X PCR Master Mix 12.5 μL N x 12.5 μL N = 10 + 1 = 11 137.5 μL 
Primer RP‐F 0.5 μL N x 0.5 μL N = 10 + 1 = 11 5.5 μL 
Primer RP‐R 0.5 μL N x 0.5 μL N = 10 + 1 = 11 5.5 μL 
RP Probe 0.5 μL N x 0.5 μL N = 10 + 1 = 11 5.5 μL 
SuperScriptTM III 
RT/Platinum®Taq Mix 
0.5 μL N x 0.5 μL N = 10 + 1 = 11 5.5 μL 
Total Volume 20 μL N x 20 μL 220 μL 
Prepare Mix on ice and add template. 
a.	 Place PCR plate on ice. 
b.	 Add 20 μL of Master Mix to each well. 
c.	 Add 5 μL of extracted sample, including HSC samples. 
d.	 Seal with optical 8‐cap strip and place plate in Applied Biosystems 7500 Fast DX Real‐time PCR 
System. 
14. CREATE A RUN TEMPLATE ON THE ABI 7500 FAST DX REAL-TIME PCR INSTRUMENT  
(REQUIRED IF NO TEMPLATES EXIST) 
If the template already exists on your instrument, please proceed to the RUNNING A TEST section. 
Otherwise, follow the process below: 
1. Launch the Applied Biosystems 7500 Fast Dx Real‐time PCR System by double clicking on the Applied 
Biosystems 7500 Fast Dx System icon on the desktop. 
2. A new window should appear, select Create New Document from the menu. 






                      
          
      
      
        
      
      
        
                      
 
                      
 
                
 
         
 
                             
                     
  
3. The New Document Wizard screen in Figure 1 will appear. Select: 
a. Assay: Standard Curve (Absolute Quantitation) 
b. Container: 96‐Well Clear 
c. Template: Blank Document 
d. Run Mode: Standard 7500 
e. Operator: Your name 
f. Comments: SSD v1.4 
g. Plate Name: Your choice 
4. After making selections, click Next at the bottom of the window. 
5. After selecting next, the Select Detectors screen (Figure 2) will appear. 
6. Click the New Detector button (see Figure 2). 
Figure 2. Creating New Detectors 
If you are running the Singleplex Assay, continue with step 7 on the next page.
 







                                    
                               
                 
 
         
 
                  
      
      
      
      
                        
                    
                      
                        
                                  
                                 
         
   
14.1 Singleplex Assay 
THE FOLLOWING STEPS ARE SPECIFIC FOR CREATING RUN TEMPLATES FOR SINGLEPLEX ASSAY
7.	 The New Detector window will appear (Figure 3). A new detector will need to be defined for each 
dengue primer and probe set. Creating these detectors will enable you to analyze each primer and 
probe set individually at the end of the reaction.
Figure 3. Creating New Detector 
8.	 Start by creating the DENV‐1 Detector. Include the following: 
a.	 Name: DENGUE 1 
b.	 Description: leave blank 
c.	 Reporter Dye: FAM 
d.	 Quencher Dye: (none) 
e.	 Color: to change the color of the detector indicator do the following: 
 Click on the color square to reveal the color chart. 
 Select black as the color by clicking on the black square. 
 After selecting color click OK to return to the New Detector screen. 
f.	 Click the New Detector button of the New Detector screen to return to the screen shown in 
Figure 3. Repeat steps 6‐8 for each DENGUE target in the Assay. Please select the colors as 













                            
                 
 
                                
                                 
               
 




                                  
       
 
         
Name Reporter Dye Quencher Dye Color 
DENGUE 1 FAM (NONE) BLACK 
DENGUE 2 VIC (NONE) BLUE 
DENGUE 3 TEXAS RED (NONE) RED 
DENGUE 4 CY5 (NONE) GREEN 
RP FAM (NONE) BROWN 
9.	 After each Detector is added, the Detector Name, Description, Reporter, and Quencher fields will 
become populated in the Select Detectors screen (Figure 4). 
10. Before proceeding, the newly created detectors must be added to the document. To add the new 
detectors to the document, click ADD (see Figure 4). Detector names will appear on the right hand 
side of the Select Detectors window (Figure 4). 
Figure 4. Adding New Detectors to Document 
11. Once all detectors have been added, select (none) for Passive Reference at the top right hand drop 
down menu (Figure 5). 





                                    
     
 
                                      
                   
 
                                      
                                 
                         
 
                          
 
         
 




12. Click Next at the bottom of the Select Detectors window to proceed to the Set Up Sample Plate 
window (Figure 6). 
13. In the Set Up Sample Plate window (Figure 6), use your mouse to select row A from the lower 
portion of the window, in the spreadsheet (see Figure 6). 
14. Then in the top portion of the window, select detector DENGUE 1. A check will appear next to the 
detector you have selected (Figure 6). You will also notice the column in the spreadsheet will be 
populated with a colored “U” icon to indicate which detector you have selected. 
15. Repeat steps 14‐15 for each detector that will be used in the assay. 
Figure 6. Sample Plate Setup 




         
 
                                  
                                 
 
 
                           
 
                                  
                           
     
 
           
 
   
Figure 7. Sample Plate Setup 
17. After clicking Finish, there will be a brief pause allowing the Applied Biosystems 7500 Fast Dx to 
initialize. This initialization is followed by a clicking noise. Note: The machine must be turned on for 
initialization. 
18. After initialization, the Plate tab of the Set up (Figure 8) will appear. 
19. Each well of the plate should contain colored U icons that correspond with the detector labels that 
were previously chosen. To confirm detector assignments, select Tools from the file menu, then 
select Detector Manager. 





                
 
         
 
                                
                   
 
                              
         
 
       
   
20. The Detector Manager window will appear (Figure 9). 
Figure 9. Detector Manager Window 
21. Confirm all dengue detectors are included and that each dengue target has a Reporter set to 
respective reporter dye and the Quencher is set to (none). 
22. If all detectors are present, select Done. The detector information has been created and assigned 
to wells on the plate. 




                       
                                    
                               
                 
 
         
 
                  
      
      
      
      
                        
                    
                      
                        
                                  
   
 




14.2 Multiplex Assay 
THE FOLLOWING STEPS ARE SPECIFIC FOR CREATING RUN TEMPLATES FOR MULTIPLEX ASSAY 
7.	 The New Detector window will appear (Figure 10). A new detector will need to be defined for each 
dengue primer and probe set. Creating these detectors will enable you to analyze each primer and 
probe set individually at the end of the reaction. 
Figure 10. Creating New Detector 
8.	 Start by creating the DENV‐1 Detector. Include the following: 
a.	 Name: DENGUE 1 
b.	 Description: leave blank 
c.	 Reporter Dye: FAM 
d.	 Quencher Dye: (none) 
e.	 Color: to change the color of the detector indicator do the following: 
f.	 Click on the color square to reveal the color chart 
g.	 Select black as the color by clicking on the black square 
h.	 After selecting color click OK to return to the New Detector screen 
i.	 Click the New Detector button of the New Detector screen to return to the screen shown in 
Figure 10 





       
     
       




                            
                 
 
                                
                                 
               
 




                                  
       
 
         
 
Name Reporter Dye Quencher Dye Color 
DENGUE 1 FAM (NONE) BLACK 
DENGUE 2 VIC (NONE) BLUE 
DENGUE 3 TEXAS RED (NONE) RED 
DENGUE 4 CY5 (NONE) GREEN 
RP FAM (NONE) BROWN 
10. After each Detector is added, the Detector Name, Description, Reporter, and Quencher fields will 
become populated in the Select Detectors screen (Figure 11). 
11. Before proceeding, the newly created detectors must be added to the document. To add the new 
detectors to the document, click ADD (see Figure 11). Detector names will appear on the right hand 
side of the Select Detectors window (Figure 11). 
Figure 11. Adding New Detectors to Document 
12. Once all detectors have been added, select (none) for Passive Reference at the top right hand drop 
down menu (Figure 12). 




                                    
     
                                      
                   
 
                                  
                                   
                                 
       
 
                          
 
                                      
                                 
                     
 
                              
 
         
 
                      
 
                                  
                                 
 
 
                           
 
                                  
                           
     
13. Click Next at the bottom of the Select Detectors (Figure 12) window to proceed to the Set Up 
Sample Plate window. 
14. In the Set Up Sample Plate window (Figure 13), use your mouse to select row A from the lower 
portion of the window, in the spreadsheet (see Figure 13). 
15. Then in the top portion of the window, select detector DENGUE 1, DENGUE 2, DENGUE 3 AND 
DENGUE 4. A check will appear next to each detector you have selected (Figure 13). You will also 
notice the column in the spreadsheet will be populated with a colored “U” icon to indicate each 
detector you have selected. 
16. Select row B from the lower portion of the window, in the spreadsheet. 
17. The in the top portion of the window, select detector RP. A check will appear next to the detector 
you have selected. You will also notice the column in the spreadsheet will be populated with a 
colored “U” icon to indicate the RP detector you have selected. 
18. Repeat steps 14‐16 for each corresponding row where samples will be located in the plate. 
Figure 13. Sample Plate Setup 
19. Select Finish after detectors have been assigned to their respective columns. 
20. After clicking Finish, there will be a brief pause allowing the Applied Biosystems 7500 Fast Dx to 
initialize. This initialization is followed by a clicking noise. Note: The machine must be turned on for 
initialization. 
21. After initialization, the Plate tab of the Set up (Figure 14) will appear. 
22. Each well of the plate should contain colored U icons that correspond with the detector labels that 
were previously chosen. To confirm detector assignments, select Tools from the file menu, then 




           
 
 
                
 
         
 
 
                                
                   
 
                                
       
 
       
Figure 14. Plate Set up Window 
23. The Detector Manager window will appear (Figure 15). 
Figure 15. Detector Manager Window 
24. Confirm all dengue detectors are included and that each dengue target has a Reporter set to 
respective reporter dye and the Quencher is set to (none). 
25. If all detectors are present, select Done. The detector information has been created and assigned to 
wells on the plate. 





                        
 
                  
 
                  
                      
                      
                      
                      
                  
                        
                  
                                  
       
 
                                    
                     
 
                                




15. DEFINING THE INSTRUMENT SETTINGS 
1.	 After detectors have been created and assigned, proceed to instrument set up. 
2.	 Select the Instrument tab to define thermal cycling conditions. 
3.	 Modify the thermal cycling conditions as follows (Figure 16): 
a.	 In Stage 1, Set to 30 min at 50°C; 1 Rep 
b.	 In Stage 2, Set to 2.0 min at 95°C; 1 Rep 
c.	 In Stage 3, Step 1 set to 15 sec at 95°C 
d.	 In Stage 3, Step 2 set to 1 min at 60.0°C 
e.	 In Stage 3 Reps should be changed to 45 
f.	 Under Settings (Figure 16), bottom left‐hand box, change volume to 25 µL 
g.	 Under Settings, Run Mode selection should be Standard 7500 
h.	 Step 2 of Stage 3 should be highlighted in yellow to indicate data collection (see Figure 16) 
Figure 16. Instrument Window 
4.	 After making changes to the Instrument tab, the template file is ready to be saved. To save the 
template, select File from the top menu, then select Save As. 
5.	 Save the template as Dengue in desktop folder labeled “ABI Run Templates” (you must create this 






       
 
 
                    
 
                                
             
 
                        
 
                      
 
              
 
                                  





Figure 17. Saving Template 
16. RUNNING A TEST 
1.	 Turn on the ABI 7500 Fast Dx Real‐time PCR instrument. 
2.	 Launch the Applied Biosystems 7500 Fast Dx Real‐time PCR System by double clicking on the 7500 
Fast Dx System icon on the desktop. 
3.	 A new window should appear, select Open Existing Document from the menu. 
4.	 Navigate to select your ABI Run Template folder from the desktop. 
5.	 Double click on the Dengue template file. 
6.	 There will be a brief pause allowing the Applied Biosystems 7500 Fast Dx Real‐time PCR system to 





                              
                       
   
7. After the instrument initializes, a plate map will appear (Figure 18). The detectors and controls 




           
 
                    
 
                  
 
                            
       
 
                           
 
                                
                 
 
                  
 
Figure 18. Plate Set up Window 
8. Click the Well Inspector icon from the top menu. 
9. Highlight specimen wells of interest on the plate map. 
10.
11. Repeat steps 9‐10 until all sample identifiers are added to the plate setup. 
12. Once all specimen and control identifiers are added click the Close button on the Well Inspector 
window to return to the Plate set up tab. 




                              
       
 
                    
 
                                    
         
 




14. The reaction conditions, volumes, and type of 7500 reaction should already be loaded (Figure 20). 
Figure 20. Instrument Settings 
15. Ensure settings are correct (refer to the Defining Instrument Settings). 
16. Before proceeding, the run file must be saved; from the main menu, select File, then Save As. Save 
in appropriate run folder designation. 






                                  
 
                        
         
 
                                          
                           
 
                                          
 
 
                              
 
                          
           
 
                        
 
              
 
                                
                               
       
 
17. DATA ANALYSIS 

1.	 After the run has completed, select the Results tab at the upper left corner of the software. 
2. Select the Amplification Plot tab to view the raw data (Figure 21). 
Figure 21. Amplification Plot Window 
3.	 Start by highlighting all the samples from the run; to do this, click on the upper left hand box (a) of 
the sample wells (Figure 21). All the growth curves should appear on the graph. 
4.	 On the right hand side of the window, (b) the Data drop down selection should be set to Delta Rn vs 
Cycle. 
5.	 Select DENGUE 1 from the (c) the Detector drop down menu using the downward arrow. 
a.	 Please note that each detector is analyzed individually to reflect different performance profiles 
of each primer and probe set. 
6.	 In the Line Color drop down, (d) Detector Color should be selected. 
7.	 Under Analysis Settings select Manual Ct (e). 
a.	 Do not change the Manual Baseline default numbers. Using the mouse, click and drag the red 
threshold line until it lies within the exponential phase of the fluorescence curves and above any 





       
 
 
                                    
             
 
                                  
         
 
                          
 
                                  
                                 











Figure 22. Amplification Plot 
8.	 Click the Analyze button in the lower right corner of the window. The red threshold line will turn 
green, indicating the data has been analyzed. 
9.	 Repeat steps 5‐9 to analyze results generated for each set of markers (i.e. DENGUE 1, DENGUE 2, 
DENGUE 3, DENGUE 4, RP). 
10. Save analysis file by selecting File then Save As from the main menu. 
11. After completing analysis for each of the markers, select the Report tab above the graph to display 
the Ct values. To filter report by sample name in ascending or descending order, simply click on 
Sample Name on the table (Figure 23). 





       
                                 
                               
                                 




                               
                                 
             
 
           
                                   
                           
                                     
             
 
     
                              
                                    
                    
                              
 
                            
 
            
        
 
                                 
                                  
                               
                                   
               
                                    
                             
18. INTERPRETATION OF RESULTS 
18.1 Extraction and Control Results and Interpretation 
No Template Control (NTC) 
The NTC consists of using nuclease‐free water in the rRT‐PCR reactions instead of RNA. The NTC reactions 
for all primer and probe sets should not exhibit fluorescence amplification curves that cross the threshold 
line. If any of the NTC reactions exhibit an amplification curve that crosses the cycle threshold, sample 
contamination may have occurred. Invalidate the run and repeat the assay with strict adherence to the 
guidelines. 
DENV‐1‐4 Positive Control 
The positive control consists of a mix of DENV‐1, ‐2, ‐3, and ‐4 dengue virus from C6/36 cell culture 
supernatant. Purified RNA from the positive control will yield a positive result with the following primer and 
probe sets: DENV‐1, DENV‐2, DENV‐3 and DENV‐4. 
Human Specimen Control (HSC) (Extraction Control) 
The HSC control consists of noninfectious cultured human cell (A549) material. The HSC is used as a RNA 
extraction procedural control to demonstrate successful recovery of RNA as well as extraction reagent 
integrity. Purified RNA from the HSC should yield a positive result with the RP primer and probe set and 
negative results with all dengue specific markers. 
RNase P (RP) 
 All clinical samples should exhibit fluorescence amplification curves in the RP reaction that cross the 
threshold line within 37 cycles (< 37 Ct), thus indicating the presence of the human RNase P gene. 
 Failure to detect RP in any clinical specimens may indicate: 
o	 Improper extraction of nucleic acid from clinical materials resulting in loss of RNA and/or RNA 
degradation. 
o	 Absence of sufficient human cellular material due to poor collection or loss of specimen 
integrity. 
o	 Improper assay set up and execution. 
o	 Reagent or equipment malfunction. 
If the RP assay does not produce a positive result for human clinical specimens, interpret as follows: 
	 If the DENV‐1, ‐2, ‐3 and ‐4 are positive, even in the presence of a negative RP, the dengue result 
should be considered valid. It is possible, that some samples may fail to exhibit RP amplification 
curves due to low levels in the original clinical sample. A negative RP signal does not preclude the 
presence of dengue virus in a clinical specimen. 
	 If all dengue markers and RP are all negative for the specimen, the assay is “inconclusive” for the 





                             
         
 
                     
 
       
                            
                                 
                       
                            
                           
                                 
                                   
                             
                             
                               
                           
 
                              
                                 
                             
                             
                               
           
 
 
                             
                               
                               
                               
                             
      
 
                               
                             
                         
                             
                               
                                   
         
all markers remain negative after retest, report the results as “inconclusive” and a new specimen 
should be collected if possible. 
The RP assay may be negative when testing virus culture samples. 
DENV Markers (DENV‐1, ‐2, ‐3 and ‐4) 
	 When all controls exhibit the expected performance, a specimen is considered negative if DENV 
marker amplification curves DO NOT cross the threshold line within 37 cycles (< 37 Ct) and RP 
amplification curve does cross the threshold line within 37cycles (< 37 Ct). 
	 When all controls exhibit the expected performance, a specimen is considered positive for either 
DENV‐1, ‐2, ‐3 or ‐4 if the DENV marker (e. g., DENV‐1, ‐2, ‐3 or ‐4) amplification curve crosses the 
threshold line within 37 cycles (<37 Ct). If more than one DENV marker crosses the threshold line 
within cycle 37 (<37 Ct), the extracted RNA from the specimen should be re‐tested. If residual RNA is 
not available, re‐extract RNA from residual specimen and re‐test. If the re‐tested sample is still 
positive for two DENV markers and all controls exhibit the expected performance, the result may 
indicate “dual DENV infection.” Dual infections have been rarely reported. If there is an indication of 
dual infection, sample should be sent to the CDC‐Dengue Branch for confirmatory testing (Email: 
ckq2@cdc.gov). 
	 When all controls exhibit the expected performance and none of the amplification curves for DENV 
markers or the RP marker cross the threshold line within 37 cycles (<37 Ct), the result is 
inconclusive. The extracted RNA from the specimen should be re‐tested. If residual RNA is not 
available, re‐extract RNA from residual specimen and re‐test. If the re‐tested sample is negative for 
all markers and all controls exhibit the expected performance, the result is “Inconclusive” and a new 
specimen should be collected if possible. 
19. STANDARD-BASED ELECTRONIC LABORATORY REPORTING FOR DENGUE 
19.1 Recommendations for Uniform Coding And Vocabulary For Diagnostic Testing 
The following information is provided to assist the performing laboratory in complying with new federal 
guidelines for the meaningful use of health information. The standardization of test information as well as 
the method for achieving electronic data exchange has become a priority for the federal government and 
healthcare systems. It is expected that a uniform approach to the terminology and exchange format for 
diagnostic assays used for the identification and characterization of pathogens that humans can acquire will 
accelerate this process. 
To achieve this goal it is necessary to harmonize human readable language and machine readable language 
through the use of common exchange protocols as well as standard vocabulary and codes. The 
implementation of adopted standards must be harmonized across all performing laboratories to ensure 
interoperability. Harmonization refers to the process of insuring that all users interpret and use the 
standards in the same way. Without this harmonization process, it is possible for different laboratories to 
implement the standards differently and thus result in the generation of data that cannot be shared or used 





                           
                                   
                           
                   
 
                     
                            
                           
                       
                     
               
                     
    
 
                               
                         
                               
                             
                           
                                 
                      
 
                             
                               
                         
                           
                         
                             
 
                           
                         
                               
                             
 
                               
                           
                               
                         
This interoperability is especially important for laboratory tests associated with diseases of public health 
importance. The ability of the local and state officials as well as the federal government to receive tests 
results associated with human case definition is critical for identifying new outbreaks and for 
epidemiological investigations needed to limit the spread of disease. 
19.2 Process for Achieving Uniformity In Laboratory Test Results 
The laboratory performing diagnostic assays may utilize a Laboratory Information Management 
Systems (LIMS) with connections to a hospital or medical system Electronic Health Record (EHR). 
The U.S. Department of Health and Human Services recommends the use of specific coding 
systems for achieving uniformity of test results incorporated into electronic messages. These 
coding systems include LOINC Logical Observation Identifiers Names and Codes (LOINC® ‐‐
(http://www.loinc.org) and SNOMED CT–Systematic Nomenclature of Medicine‐‐Clinical Terms 
(http://www.ihtsdo.org/). These coding systems have specific capabilities that are essential for 
achieving uniformity. 
Standard English terminology for the test name and text results have been established by the CDC 
developer of this assay through collaboration with the testing community and expert knowledge 
of the processes involved. It is recognized that this terminology will differ in countries outside the 
United States. However, through the use of national and international agreements, it is possible to 
establish a universal set of codes and terms to accurately characterize laboratory observations. At 
this time, there are no recommendations that apply to the reporting of results of this assay within 
the United States, but they may be available in the future. 
LOINC provides for a common understanding of the medical procedure or process related to the 
specific assay, in this case the process of detecting the presence of dengue virus serotypes 1‐4. 
The LOINC codes describe the specific molecular methodology employed by the assay; recovery 
and amplification of an RNA target and that multiple targets are employed. This approach 
unambiguously distinguishes the test from other molecular assays so that the manufacturer and 
the FDA can track its performance in comparison with other assays in the future. 
SNOMED CT codes provide for unambiguous representation of the test results and allow the 
application of specific concepts such as “detected” or “positive”. Theses codes provide for 
description of the source or location of the specimen being tested. Also specified are terms for 
conveying information about failures of the test procedure or the lack of adequate specimen. 
It is recommended that the LOINC test code and the test results, represented by SNOMED codes, 
be incorporated into a Health Level 7 (HL7) standardized laboratory test message format for 
electronic routing of results to and from HL7 compliant systems. This would achieve the goal of 




                       
                   
 
                               
                             
                           
                           
                         
                         









             
   
             
       
                                       
                                    
                               
           
	 	
harmonized human readable language and machine readable language through the use of 
common exchange protocols as well as standard vocabulary and codes. 
The test result message for this assay includes results from all component tests and a conclusion 
or interpretation. The results are to be incorporated into a standard Health Level 7 (HL7) 
electronic format for laboratory test messaging. More information about HL7 can be found at 
http://www.hl7.org. Several versions of HL7 exist and there are several implementations in use for 
each version. Examples of public health messaging systems currently using a constrained version 
of HL7 v2.3.1 ORU^R01 message to report results can be viewed at PHINVADS: 
http://phinvads.cdc.gov/vads. All related vocabulary can be found as a view and downloaded 
from: https://phinvads.cdc.gov/vads/ViewCodeSystem.action?id=2.16.840.1.114222.4.5.277. 
20. CDC DENV-1-4 REAL-TIME RT-PCR ASSAY USERS GUIDE FOR INTERPRETATION OF RESULTS 
QUICK REFERENCE AND REPORTING 
DENV‐1 DENV‐2 DENV‐3 DENV‐4 RP Target Report 
+ ‐ ‐ ‐ ± Positive DENV‐1 detection* 
‐ + ‐ ‐ ± Positive DENV‐2 detection* 
‐ ‐ + ‐ ± Positive DENV‐3 detection* 
‐ ‐ ‐ + ± Positive DENV‐4 detection* 
‐ ‐ ‐ ‐ + Negative for DENV, result does not 
preclude infection 
‐ ‐ ‐ ‐ ‐ Inconclusive test, likely poor 
extraction or sample quality** 
* If sample is positive for 2 serotypes, repeat test as indicated above. If sample is repetitively reactive for both 
serotypes the result may be indicative of a dual infection and should be confirmed by the CDC‐Dengue Branch. 
** When an inconclusive result is obtained, re‐extract the specimen and test the newly extracted RNA 





                          
                       
                             
                   
                       
             
                      
                                    
           
                            
   
                                
                                
       
	
 
                                  
                         
                   
                                    
                         
                                   
           
                                
                               
               
                  
                            
                                    
       
                                    
       
                            
                           
                             
             
	
21. QUALITY CONTROL 
	 Quality control requirements must be performed in conformance with local, state, and federal 
regulations or accreditation requirements and the user laboratory’s standard quality control procedures. 
It is recommended that the user refer to CLSI document C24‐A2, Statistical Quality Control for 
Quantitative Measurements: Principles and Definitions: [Approved Guideline‐Second Edition] or other 
published guidelines for general quality control recommendations. For further guidance on appropriate 
quality control practices, refer to 42CFR 493.1202(c). 
	 Quality control procedures are intended to monitor reagent and assay performance. 
	 Test all positive controls prior to running diagnostic samples with each new kit lot to ensure all reagents 
and kit components are working properly. 
	 Good laboratory practice (cGLP) recommends including a positive extraction control in each nucleic acid 
isolation batch. 
	 HSC extraction control must proceed through nucleic acid isolation per batch of specimens to be tested. 
	 Always include a negative control (NTC), and the appropriate positive control (DENV‐1 – 4) in each 
amplification and detection run. 
22. LIMITATIONS 
	 This device is subject to a special control requiring that distribution be limited to laboratories with (i) 
experienced personnel who have training in standardized molecular testing procedures and expertise in 
viral diagnosis, and (ii) appropriate biosafety equipment and containment (21CFR866.3332(b)(2)). 
	 Negative results do not preclude dengue virus infection and should not be used as the sole basis for 
treatment or other patient management decisions. A negative specimen collected between days 3‐7 
after onset of the febrile illness should be retested with an anti‐DENV IgM test to increase the likelihood 
of making the diagnosis of dengue. 
	 A false negative result may occur if a specimen is improperly collected, transported or handled. False 
negative results may also occur if amplification inhibitors are present in the specimen or if inadequate 
numbers of organisms are present in the specimen. 
	 Do not use any reagent past the expiration date. 
	 The performance of this test has not been established for monitoring treatment of dengue. 
	 The performance of this test has not been established for screening of blood or blood product for the 
presence of DENV infection. 
	 Detection of viral RNA may not indicate the presence of infectious virus or that dengue is the causative 
agent for clinical symptoms. 
	 This test cannot rule out diseases caused by other bacterial, viral or parasitic pathogens. 
•	 Assay performance characteristics have not been established for prenatal screening, or for general 
population screening without symptoms consistent with Dengue Fever. The test is not FDA cleared for 






                                 
                                 
                                 
                               
                               
                         
                           
                               
                           
                         
                       
 
                           





                         
                             
                           
                                         
                               
                                 
                                       
                       
                       






23. EXPECTED VALUES 
The percent of positive cases identified by the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay will vary depending on 
nature of the surveillance process, given that an unknown proportion of febrile cases reported may not be 
dengue. It is expected that the proportion of serotypes identified will vary with time, location and patient 
population. In dengue endemic areas, usually one serotype may be more prevalent than the others. A 
serotype may not be detected for long periods and then re‐emerge and become the predominant serotype. 
Different countries may have different serotype predominance; therefore travelers returning to the United 
States from dengue‐endemic countries may have been infected with different serotypes. Puerto Rico has 
had the four DENV serotypes circulating at different times. During the 2007 epidemic, DENV‐2, and DENV‐3 
were the predominant serotypes and during the 2010 epidemic, DENV‐1 and DENV‐4 were predominant. 
Florida has experienced autochthonous DENV‐1 transmission in 2009 and 2010; and travel‐associated cases 
(Florida residents travelling internationally) have been identified with DENV‐1, DENV‐2 and DENV‐4. 
In serologically confirmed cases, the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay positively identified 93% of 
cases. A 97% agreement between positive results on the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay and 
sequencing was obtained. 
24. PERFORMANCE CHARACTERISTICS 
24.1 Clinical Performance 
Prospective Studies 
Performance characteristics of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay were established during a 
prospective study at 3 public health laboratories (2009‐2011). A total of 86 serum samples were 
prospectively collected from dengue‐suspected, febrile patients during the first 5 days of symptoms and 
were tested at the three sites. There were twenty five (25) and thirty six (36) serum samples tested at Site 1 
and 3 respectively using the Qiagen QIAamp® DSP Viral RNA Mini Kit (cat# 61904) extraction procedure 
following the manufacturer’s protocol. Twenty five (25) serum samples were tested at Site 2 using the Roche 
MagNA Pure LC total Nucleic Acid Isolation Kit (03 038 505 001). The eluted viral RNA was tested using the 
Invitrogen SuperScript®III Platinum OneStep Quantitative RT‐PCR System (cat# 11732‐088) on the Applied 
Biosystems® 7500 FAST DX thermocycler. All 86 samples subsequently underwent bi‐directional sequencing 























                                 




                           
                             
                             
                                 
                                   
                           
                             
                           
 
                                   
                         
                         
                           
                             
                             
                             
                               
                               
                           
               
             






       
         
         
Overall Prospective Comparison Results 
Multiplex CDC DENV‐1‐4 Real‐Time RT‐PCR Assay Comparison Results 
Reference Method (Sequencing) 
Positive Negative Total 
CDC DENV‐1‐4 Real‐
Time RT‐PCR Assay 
Positive 47 0 47 
Negative 1* 38 39 
Total 48 38 86 
Value 95% Confidence Interval 
Positive percent agreement 97.92% (47/48) 89.10% ‐ 99.63% 
Negative percent agreement 100% (38/38) 90.82% ‐ 100% 
*One sample was negative on the CDC‐DENV‐1‐4 RT‐PCR assay which was positive for DENV‐3 by E gene bi‐
directional sequencing. All other negative RT‐PCR samples were also negative by E gene bi‐directional 
sequencing. 
Retrospective Studies 
The performance characteristics of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay were established during a 
retrospective study at the CDC Dengue Branch. Three hundred seventy one serum samples were obtained 
from the archived CDC routine dengue surveillance specimens collected in pairs during 2007‐2011. The first 
sample (acute) was collected during the first five days of illness, and the second sample (convalescent) was 
obtained at least 6 days after the onset of symptoms. These samples were tested with the IgM anti‐DENV 
Capture Enzyme Linked Immunosorbent Assay (CDC MAC‐ELISA – validated in‐house) in order to establish 
seroconversion. The results of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay (Multiplex) obtained for the acute 
samples were compared to the IgM anti‐DENV seroconversion results in the paired samples. 
Nucleic acid from all acute samples was extracted using the Qiagen QIAamp® DSP Viral RNA Mini Kit (cat# 
61904) following manufacturer’s protocol. Each nucleic acid sample was tested following the procedure 
described for the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay (Multiplex) using the Invitrogen SuperScript®III 
Platinum OneStep Quantitative RT‐PCR System (cat# 11732‐088) on the Applied Biosystems® 7500 FAST DX 
thermocycler. The percent agreement is calculated for the number of samples that received positive or 
negative results in the CDC DENV‐1‐4 RT‐PCR assay and using IgM anti‐DENV seroconversion as a 
comparator. In addition, bi‐directional sequencing of the DENV E gene (1485 bp) was obtained, and 
corroborated the results of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay on all positive samples except for 
one. The following table summarizes the results obtained on the 371 specimens that originated from the 
following sources: non‐United States dengue cases (n=39); Puerto Rico dengue cases (n=82); 250 negative 




                                 











        
       
 
            
       
 
            
                               
                             
                             
                           
                               
                               
                                 
          
 
                               
                                   
                             
                             
                                 
                                         
                                     
                                   
                                 
                                       
                               




Overall Retrospective Comparison Results 
Multiplex CDC DENV‐1‐4 Real‐Time RT‐PCR Assay Comparison Results 
Reference Method 
(IgM anti‐DENV Conversion) 
Positive Negative Total 
CDC DENV‐1‐4 
Real‐Time RT‐PCR Assay 
Positive 100* 4*** 104 
Negative 2** 265 267 
Total 102 269 371 
Value 95% Confidence Interval 
Positive percent agreement 98.04% 
(100/102) 
93.13% ‐ 99.46% 
Negative percent agreement 98.51% 
(265/269) 
96.24‐ 99.42% 
*One DENV‐1 case was positive on the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay (multiplex) and confirmed positive 
by IgM anti‐DENV conversion, but not sequenced effectively enough to produce an interpretable result. **Two 
samples were negative by the CDC‐DENV‐1‐4 Real‐Time RT‐PCR Assay (multiplex). One of these samples was 
DENV‐3 positive by the CDC‐DENV‐1‐4 Real‐Time RT‐PCR Assay (singleplex) and was further confirmed DENV‐3 
positive by sequencing. The other sample was confirmed DENV‐3 positive by sequencing. *** Four samples had 
positive RT‐PCR results but were not confirmed by IgM anti‐DENV seroconversion. Two of these samples were 
positive for DENV‐3 and the other two samples were positive for DENV‐4 positive. These results were confirmed 
by E gene bi‐directional sequencing. 
24.2 Reproducibility 
The reproducibility of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay was evaluated at three testing sites (the 
CDC Dengue Branch Lab and two external independent sites). Operator to operator, run to run and site to 
site reproducibility were evaluated using five test panels which include negative, high negative, low positive, 
and moderate positive samples. In order to develop these panels, cultured, quantified (pfu/mL) stocks of 
whole virus (strains DENV‐1 Haw, DENV‐2 NGC, DENV‐3 H87 and DENV‐4 H241) were used. Each sample of 
the panel was tested twice a day for at least 5 days by two operators with each operator running the panel 
members two times a day. Test operators were blinded with respect to test panel members for each run and 
device lot to ensure that panel results could not be predicted by the operator. Two RNA extraction methods 
validated for the CDC DENV‐1‐4 RT‐PCR were used in the reproducibility study. The CDC Dengue Branch Lab 
and one external site used the Qiagen QIAamp® DSP Viral RNA Mini Kit and a second external site used the 
MagNA Pure LC total Nucleic Acid Isolation Kit. The manufacturer’s instructions for use provided in the 






                                 




















         
         
         




         
         
         




         
         
         




         
         
         
       
 
 
       
 
                    
             
   
Reproducibility Studies for the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay at three sites on the ABI 7500 Fast 
Dx Real‐Time PCR Instrument and SSD version 1.4 Software 
Site 1 Site 2 Site 3 













DENV‐1 Moderate Positive 24.23 5.24 20/20 25.83 2.40 20/20 17.91 3.96 20/20 
Low Positive 30.45 3.68 19/20 31.15 1.32 19/20 21.28 3.34 20/20 
High Negative 38.75 3.51 16/20 38.70 4.16 15/20 19.41 5.87 16/20 
Negative NA NA 20/20 NA NA 20/20 38.54* NA 19/20 
DENV‐2 Moderate Positive 26.89 5.09 20/20 24.97 2.76 20/20 18.65 5.52 20/20 
Low Positive 32.02 3.94 18/20 30.80 3.21 19/20 22.27 4.63 20/20 
High Negative 40.24 2.91 14/20 38.08 2.42 17/20 19.72 8.01 15/10 
Negative NA NA 20/20 39.22* NA 20/20 41.72* NA 19/20 
DENV‐3 Moderate Positive 25.53 4.97 20/20 25.25 4.32 20/20 18.51 4.16 20/20 
Low Positive 30.62 3.66 20/20 30.88 2.33 20/20 21.56 3.57 20/20 
High Negative 38.91 3.16 15/20 38.49 4.65 16/20 21.10 5.73 16/20 
Negative NA NA 20/20 39.71* NA 20/20 38.63* NA 19/20 
DENV‐4 Moderate Positive 24.83 4.27 20/20 25.46 3.61 20/20 17.78 6.13 20/20 
Low Positive 30.10 2.82 19/20 30.40 6.09 19/20 21.30 3.62 19/20 
High Negative 39.14 3.68 14/20 38.02 3.10 15/20 26.90 8.18 17/20 
Negative NA NA 20/20 NA NA 20/20 NA NA 20/20 
Neg. 
Control 
NA NA 20/20 NA NA 20/20 NA NA 20/20 
NA: Not applicable (samples did not obtain a CT value). 





                               


















       






       






       






         
 
 
                   
 
     
                               
                                   
                           
                                   
                                 
                         
                          
 
                                   
                
 
 
Reproducibility Study Summary for the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay on the ABI 7500 Fast Dx 
Real‐Time PCR Instrument and SSD version 1.4 Software 
AVG CT %CV 
Agreement with 
Expected Result 95% CI 
DENV‐1 Moderate Positive 25.52 3.41 60/60 (100 %) 94.0 ‐ 100 
Low Positive 31.03 2.42 58/60 (96 %) 88.6 ‐ 99.11 
High Negative 38.60 3.55 47/60 (21 %) 15.9 ‐ 39.6 
Negative 38.54* NA 60/60 (100 %) NA 
DENV‐2 Moderate Positive 26.32 3.91 60/60 (100 %) 94.0 ‐ 100 
Low Positive 31.77 3.43 57/60 (95 %) 86.3 ‐ 98.29 
High Negative 38.91 3.14 46/60 (23%) 14.4 ‐ 35.4 
Negative 40.32* NA 60/60 (100 %) NA 
DENV‐3 Moderate Positive 26.01 5.96 60/60 (100 %) 94.0 ‐ 100 
Low Positive 31.10 4.57 60/60 (100 %) 94.0 ‐ 100 
High Negative 39.25 3.59 45/60 (25%) 15.8 ‐ 37.23 
Negative 39.17* NA 60/60 (100 %) NA 
DENV‐4 Moderate Positive 25.47 4.00 60/60 (100 %) 94.0 ‐ 100 
Low Positive 30.62 3.89 57/60 (95 %) 86.3 ‐ 98.29 
High Negative 38.62 4.17 46/60 (23%) 14.4 ‐ 35.4 
Negative NA NA 60/60 (100 %) NA 
Neg. 
Control NA NA 10/10 (100 %) NA 
*AVG CT value is based on one or two samples. 
24.3 Analytical Sensitivity 
Limit of Detection 
The limit of detection (LoD) of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay (Singleplex) was determined using 
a 5‐replica panel of viruses serially diluted in human serum or plasma at 1:10 dilutions. The panels were 
prepared from cultured, quantified (pfu/mL) stocks of whole virus (strains DENV‐1 Haw, DENV‐2 NGC, DENV‐
3 H87, DENV‐4 H241). Viral RNA from all replica samples was extracted using the Qiagen QIAamp® DSP Viral 
RNA Mini Kit on the Qiagen QIAcube. Each viral RNA elution was tested following the procedure described 
for the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay using the Invitrogen SuperScript®III Platinum OneStep 
Quantitative RT‐PCR System (cat# 11732‐088) on the Applied Biosystems® 7500 FAST DX thermocycler. 
The observed LoD of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay (Singleplex) in serum and plasma was 1 x103 






























       
       
        
       
       
         
         





       
       
       
       
       
         
         






       
       
       
       
       
         
         






       
       
       
       
       
         
         
         
 


















107 21.67 0.29 5/5 100% 22.46 0.32 5/5 100% 
106 26.15 0.23 5/5 100% 26.82 0.23 5/5 100% 
105 30.90 0.73 5/5 100% 31.47 0.76 5/5 100% 
104 34.65 2.14 5/5 100% 35.40 0.89 5/5 100% 
103 36.36 1.73 5/5 100% 35.82 3.20 5/5 100% 
102 N/A N/A 0/5 0 N/A N/A 0/5 0 
101 N/A N/A 0/5 0 N/A N/A 0/5 0 
100 N/A N/A 0/5 0 N/A N/A 0/5 0 
DENV‐2 
107 21.65 0.23 5/5 100% 21.12 0.26 5/5 100% 
106 24.74 0.31 5/5 100% 24.36 0.28 5/5 100% 
105 28.83 0.27 5/5 100% 27.15 0.26 5/5 100% 
104 31.75 0.52 5/5 100% 32.39 0.84 5/5 100% 
103 35.78 0.23 5/5 100% 36.56 0.67 5/5 100% 
102 39.67 N/A 0/5 0 39.6 N/A 0/5 0 
101 41.9 N/A 0/5 0 42.5 N/A 0/5 0 
100 N/A N/A 0/5 0 N/A N/A 0/5 0 
DENV‐3 
107 20.67 0.25 5/5 100% 22.21 0.38 5/5 100% 
106 24.18 0.77 5/5 100% 25.34 0.27 5/5 100% 
105 28.48 0.55 5/5 100% 29.39 0.14 5/5 100% 
104 32.27 0.73 5/5 100% 32.85 0.18 5/5 100% 
103 36.58 1.32 4/5 80% 35.36 1.03 5/5 100% 
102 39.71 N/A 0/5 0 38.36 0.06 3/5 60% 
101 42.01 N/A 0/5 0 41.87 N/A 0/5 0 
100 N/A N/A 0/5 0 N/A N/A 0/5 0 
DENV‐4 
107 22.46 0.13 5/5 100% 24.75 0.18 5/5 100% 
106 26.33 0.48 5/5 100% 28.20 0.12 5/5 100% 
105 29.64 0.83 5/5 100% 31.29 0.40 5/5 100% 
104 32.61 0.49 5/5 100% 34.05 1.33 5/5 100% 
103 36.68 0.46 5/5 100% 36.72 1.18 5/5 100% 
102 39.55 N/A 0/5 0 38.73 2.34 1/5 20% 
101 N/A N/A 0/5 0 N/A N/A 0/5 0 




                               
                                 
                           
                                   
                             
 
                           
                    
                                 
                                 
                             
                                   
                             
                             
                         
            
 
                                     
                                 
                         
 
                           
                             
                                 
                                 
                             
                                 
                               
                             
                     
                        
 
                                 
                                 
                  
 
                                 
                                 
                                   
               
The LoD of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay (Multiplex) was also determined using a 5‐replica 
panel of viruses serially diluted into dengue negative human serum or plasma as described for the CDC 
DENV‐1‐4 Real‐Time RT‐PCR Assay (Singleplex). The LoD of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay 
(Multiplex) in serum and plasma was shown similar (1 x 103 pfu/mL) to the CDC DENV‐1‐4 Real‐Time RT‐PCR 
Assay (Singleplex) using a manual RNA extraction method (Qiagen QIAamp® DSP Viral RNA Mini Kit). 
LoD of CDC DENV‐1‐4 Real‐Time RT‐PCR Assay (Multiplex) using an automated RNA extraction method 
(Qiagen QIAamp® DSP Viral RNA Mini Kit and Qiagen QIAcube) 
The LoD of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay (Multiplex) was established using a 5‐replica panel of 
viruses sequentially diluted in human serum or plasma at 1:10 dilutions. In order to develop these panels, 
cultured, quantified (pfu/mL) stocks of whole virus (strains DENV‐1 Haw, DENV‐2 NGC, DENV‐3 H87, DENV‐4 
H241) were used. Viral RNA from all replica samples was extracted using the Qiagen QIAamp® DSP Viral RNA 
Mini Kit (cat# 61904) on the Qiagen QIAcube (cat# 9001292) following manufacturer’s protocol. Each viral 
RNA elution was tested following the procedure described for the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay 
using the Invitrogen SuperScript®III Platinum OneStep Quantitative RT‐PCR System (cat# 11732‐088) on the 
Applied Biosystems® 7500 FAST DX thermocycler. 
The LoD of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay (Multiplex) in serum and plasma was similar (1 x 103 
pfu/mL) for both RNA extraction methods: using an automated (Qiagen QIAamp® DSP Viral RNA Mini Kit and 
Qiagen QIAcube) or a manual procedure (Qiagen QIAamp® DSP Viral RNA Mini Kit). 
LoD of CDC DENV‐1‐4 Real‐Time RT‐PCR Assay (Multiplex) using an automated RNA extraction method 
(MagNA Pure LC Total Nucleic Acid Isolation Kit on the MagNA Pure LC 2.0 Instrument) 
The LoD of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay (Multiplex) was established using a 5‐replica panel of 
viruses sequentially diluted in human serum or plasma at 1:10 dilutions. In order to develop these panels, 
cultured, quantified (pfu/mL) stocks of whole virus (strains DENV‐1 Haw, DENV‐2 NGC, DENV‐3 H87, DENV‐4 
H241) were used. Viral RNA from all replica samples was extracted using Roche MagnaPure LC 2.0 total 
Nucleic Acid Isolation Kit (03 038 505.001) on the Roche Magna Pure LC 2.0 instrument following 
manufacturer’s protocol. Each viral RNA elution was tested following the procedure described for the CDC 
DENV‐1‐4 Real‐Time RT‐PCR Assay using the Invitrogen SuperScript®III Platinum OneStep Quantitative RT‐
PCR System (cat# 11732‐088) on the Applied Biosystems® 7500 FAST DX thermocycler. 
The LoD of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay (Multiplex) in serum and plasma was observed similar 
(1 x 103 pfu/mL) using an automated viral RNA extraction method (MagNA Pure LC total Nucleic Acid 
Isolation Kit on the MagNA Pure LC 2.0 instrument). 
There was no difference in the LoD of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay (Multiplex) using three 
viral extraction methods ‐ an automated MagNA Pure LC total Nucleic Acid Isolation Kit on the MagNA Pure 
LC 2.0 instrument, an automated Qiagen QIAamp® DSP Viral RNA Mini Kit and Qiagen QIAcube, or a manual 





                                     
                              
                                     
                                   
                                 
                                 
             
 







In order to assess if the CDC DENV‐1‐4 Real Time RT‐PCR detects a variety of currently circulating strains, the 
observed LoD of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay was further confirmed using additional DENV 
1 – 4 strains. Twenty nine DENV 1 – 4 isolates obtained from patients from different countries were cultured 
and quantified. The quantified stocks were serially diluted in human serum at 1:10 dilutions to 103 and 102 
pfu/mL and were tested. Triplicate samples of each dilution were tested by the CDC DENV‐1‐4 Real Time RT‐
PCR Assay (Multiplex). The observed LoD of the CDC DENV‐1‐4 RT‐PCR Assay was similar in cultured isolates. 
Results are shown in the table below. 






                                 
                             
                             
                               
                         
                               
                               
                               
                               
                                 
                                   
                       
                           
                                   
                         
 























24.4 Analytical Specificity 
Cross Reactivity 
The analytical specificity of the CDC DENV‐1‐4 Real Time RT‐PCR Assay was evaluated by testing the device 
with nucleic acids extracted from 12 organisms representing common pathogens present in blood, serum or 
plasma samples of patients with febrile illness included in the differential diagnosis of dengue. These 
pathogens were obtained from CDC repositories. Ten of these pathogens were used to spike human serum 
(confirmed negative for dengue virus) at the clinically significant concentrations. These 10 organisms 
included four RNA arboviruses (West Nile virus [WNV], yellow fever virus [YFV], Saint Louis encephalitis virus 
[SLEV], and Chikungunya virus [CHIKV]), of which WNV, YFV and SLEV are flaviviruses related to DENV. 
Herpes simplex virus 1 and 2 (HSV‐1 and ‐2), cytomegalovirus (CMV), and varicella zoster virus (VZV) are 
DNA viruses selected for this study. Two bacterial organisms, Leptospira and Borellia, were also spiked in 
serum for cross reactivity studies. The CDC DENV‐1‐4 Real Time RT‐PCR Assay was performed on all 12 
sample triplicates. RNA was extracted using the Qiagen QIAamp® DSP Viral RNA Mini Kit and was tested with 
the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay using the Invitrogen SuperScript®III Platinum OneStep 
Quantitative RT‐PCR System on the Applied Biosystems® 7500 FAST DX thermocycler. Negative results were 
obtained with the CDC DENV‐1‐4 Real Time RT‐PCR Assay in all triplicate samples for all 12 tested organisms. 
No cross‐reactivity was observed with any panel member tested at clinically significant concentrations.
Pathogen Sample type Concentration DENV RT‐PCR 
Rate positive 
Virus pfu/ml 
WNV spiked serum 6.9x107 0/3 
YFV spiked serum 3.7x106 0/3 
SLEV spiked serum 3.7x106 0/3 
CHIKV spiked serum 4.0x106 0/3 
HCV clinical serum Unknown 0/3 
HAV clinical serum Unknown 0/3 
HSV‐1 spiked serum 1.0x105 0/3 
HSV‐2 spiked serum 1.0x105 0/3 
CMV spiked serum 1.0x105 0/3 
VZV spiked serum 1.0x105 0/3 
Bacteria bacteria/ml 
Leptospira spiked serum 2.5 x105 0/3 
Borrelia 
burgdorferi 






                             
                             
                               
                             
                                       
                             
                             
                           
    
 
                                 
                             
                       
                             
                 
 
                               
                                 
                           
                           
                                 
                                   
                         
                           
                             




Performance of the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay was characterized in the presence of potential 
interfering substances which could reasonably be expected to be present in serum and plasma specimens. 
All interference studies were carried out in the presence of cultured, quantified (pfu/mL) stocks of whole 
virus (strains DENV‐1 Haw, DENV‐2 NGC, DENV‐3 H87, DENV‐4 H241) diluted to concentrations 1:10 higher 
than the LoD dilution, equal to the LoD dilution, and the 1:10 dilution below the LoD. Each viral dilution was 
tested three times in normal human serum (NHS) or in NHS containing bilirubin (342 μmol/L), cholesterol 
(13 mmol/L), hemoglobin (2 g/L), triglycerides (37 mmol/L) and genomic DNA (400 μg/100 mL). The levels 
tested for each endogenous substance were based on the Clinical Laboratories institute (NCCLS) standard, 
EP7‐A2 (2005). 
Viral RNA from every sample was extracted using the Qiagen QIAamp® DSP Viral RNA Mini Kit. Extracted 
viral RNAs were tested following the procedure described for the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay 
using the Invitrogen SuperScript®III Platinum OneStep Quantitative RT‐PCR System on the Applied 
Biosystems® 7500 FAST DX thermocycler. No interference was observed in the presence of the described 
potential interfering substances tested at the concentrations specified above. 
24.5 Carry Over/Cross Contamination 
To assess possible cross‐contamination of samples in the CDC DENV‐1‐4 Real Time RT‐PCR Assay, 8 replica 
sets of DENV‐1 Haw, DENV‐2 NGC, DENV‐3 H87, DENV‐4 H241 were tested in an alternating series. Cultured, 
quantified (pfu/mL) stocks of DENV‐1, ‐2, ‐3 and 4 were diluted to high‐positive (107 pfu/ml) and high‐
negative (5x102 pfu/ml) concentrations. Eight high‐positive and 8 high‐negative replicas were tested in an 
alternating series by the CDC DENV‐1‐4 Real Time RT‐PCR Assay. Viral RNA from all replica samples was 
extracted using the Qiagen QIAamp® DSP Viral RNA Mini Kit. Each viral RNA elution was tested following the 
procedure described for the CDC DENV‐1‐4 Real‐Time RT‐PCR Assay using the Invitrogen SuperScript®III 
Platinum OneStep Quantitative RT‐PCR System on the Applied Biosystems® 7500 FAST DX thermocycler. All 
results were as expected. Negative samples tested were negative (32/32) and positive samples were positive 
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27. CONTACT INFORMATION, ORDERING, AND PRODUCT SUPPORT 
FOR TECHNICAL AND PRODUCT SUPPORT, CONTACT THE CDC DENGUE BRANCH SUPPORT TEAM DIRECTLY: 
For Technical Support 
Send Email to: DenguePCRSupport@cdc.gov 
For Ordering: 
Send Email to: DenguePCROrdering@cdc.gov 
Include the following information in your message: 
Laboratory name and address
 
Qualified contact person
 
Phone number
 
Email address
 
Shipping address
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